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The “Smith Surgical Papyrus” transcribed in theyears 3000 to 2500 bc contains the first written
report on surgery of the esophagus. The papyrus was
discovered by the American Egyptologist Edwin
Smith in 1862 and further meticulously edited by
Henry Breasted in 1930.1 Case 28 of the 48 cases
described in this work was entitled “A Gaping
Wound of the Throat Penetrating the Gullet” and
tells us: “. . . if thou examinest a man having a gaping
wound in his throat, piercing through to his gullet; if
he drinks water he ‘chokes’ (and) it comes out of the
mouth of his wound; if it is greatly inflamed so that
he develops fever from it, thou shouldst draw to-
gether that wound with stitching . . .”
Only 2000 years later in the seventeenth century
cervical esophagotomy was first performed and
resection of the thoracic esophagus had to wait
until the introduction of intratracheal anesthesia
well into the twentieth century. The real progress
came as a result of the development of thoracic
surgery during and after the Second World War.
Inasmuch as I had the privilege to be trained by
Mr. Ronald Belsey in Bristol, I was able to stand
on the shoulders of a true giant in esophageal
surgery and witness the remarkable developments
that were taking place. This unique experience
allowed me to build up my own practice in
esophageal surgery, thereby actively participating
in the more recent evolutions and capturing my
fascination until today. This honored guest ad-
dress is the reflection of my thoughts on esopha-
geal surgery at the end of the MILLENNIUM,
thoughts in part based on my own experience now
dealing with more than 2500 cases and in part on
the work of so many other “esophagolists.”
Esophageal atresia
The earliest description of esophageal atresia with
tracheoesophageal fistula was made in 1697, 300
years ago, by Gibson in London.2 The condition was
destined to remain an anatomic curiosity until the
first half of the century, when on March 15, 1941, C.
Haight at the University of Michigan was the first to
perform a successful one-stage closure of the fistula
and primary anastomosis.3 The further spectacular
improvements in treating this condition are a re-
markable example of the progress of modern tho-
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1
racic surgery and preoperative and perioperative
neonatal care: the epitome of modern surgery.
The most common form of esophageal atresia is
combining the atresia with a tracheoesophageal
fistula of the distal segment, occurring in approxi-
mately 85% of the cases, followed by atresia without
a fistula, usually a long-gap atresia, occurring in
approximately 10%, data that are confirmed by the
experience that my colleagues and I obtained in
dealing with 203 cases (Fig. 1).
Association with other congenital malformations
is frequently seen and they can be life threatening in
as much as 20% of the cases. Prematurity, associ-
ated malformations, and pulmonary status at the
time of surgical correction are considered as the
three essential prognostic parameters; therefore,
since the sixties they have been incorporated in a
classification named after Waterston.4 This classifi-
cation remains a valid way to judge the progress that
has been made over the years in controlling postop-
erative mortality.
Today, in patients who have no or non-life-
threatening associated malformation(s) and who are
in good general condition at the time of surgery, no
mortality is to be expected. In our own experience
over the years, overall mortality decreased from
20% to 5.4% (Table I). The most difficult technical
problem today relates to the long-gap atresia when
primary anastomosis becomes impossible. In such a
situation there are essentially two alternatives—
elongation with delayed primary anastomosis5 or
colon interposition.6 The first option fell into disfa-
vor because of the high incidence of postoperative
complications and severe gastroesophageal (GE)
reflux in the late follow-up7; thus colon interposition
now is preferred, with the technique described by
Belsey. Twenty-five patients underwent a colo-
plasty.8 In the immediate postoperative period,
anastomotic dysphagia (56%), regurgitation (40%),
and diarrhea (28%) were frequent but gradually
decreased to 16%, 20%, and 12%, respectively. At
final evaluation, 85% of the patients were consid-
ered to have excellent or very good results and only
four patients were judged to have a moderate result.
During long-term follow-up after primary anasto-
mosis, most of the residual symptoms are caused by
the atresia-related motor disorders of the esopha-
geal body, GE reflux, and pulmonary disorders, the
Fig. 1. Esophageal atresia in 203 patients. Incidence of different types of atresia.
Table I. Esophageal atresia: Waterston classification and postoperative mortality in 201 patients
1969-1979 1980-1981 1988-1996 Overall
A 2/17 (11.7%) 0/25 (0%) 0/23 (0%) 2/65 (3%)
B 4/31 (13%) 1/21 (4.7%) 0/28 (0%) 5/80 (6%)
C 8/21 (38%) 4/19 (21%) 3/16 (18.7%) 15/56 (26.7%)
Total 14/69 (20%) 5/65 (7.7%) 3/67 (4.4%) 22/201 (11%)
A, Birth weight greater than 2500 gm; good general condition. B, Birth weight 1800 to 2500 gm; good general condition. Birth weight greater than 2500 gm,
moderate pneumonia, and/or non-life-threatening congenital malformations. C, Birth weight less than 1800 gm; good general condition. Birth weight 1800
to 2500 gm, severe pneumonia, and/or life-threatening congenital malformations.
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latter enhanced by congenital deficiency of the
ciliated epithelium in the trachea. However, most
frequently the combination of both esophageal and
pulmonary symptoms is noticed. This is mainly
caused by GE reflux resulting in inflammation and
recurrent anastomotic stricture on one hand and in
regurgitation and aspiration on the other hand.
In a group of 63 patients followed up for at least
3 years, 57% became completely symptom-free. Of
the 27 patients who had symptoms, 20 (74%) had
both esophageal and pulmonary symptoms. In that
subset of 20 patients, 15 (75%) had a documented
GE reflux necessitating either aggressive medical
treatment (11 patients) or antireflux surgery (4
patients). The treatment resulted in cure or clear
improvement of the symptoms in 11 of the 15
patients (73%).
The importance of an aggressive policy to stop
any further damage of the lungs is well illustrated by
an analysis of pulmonary function tests in a group of
47 patients followed up between 6 and 13 years after
surgery.9 Only 23% had normal function tests, and
as many as 25% of the patients who had abnormal
function tests also had symptoms.
Factors influencing significantly pulmonary func-
tion were prematurity, low birth weight reflecting
prematurity, use of preoperative contrast medium,
and colon interposition, the latter because of two
thoracotomies in a number of patients. All these
factors had a mostly restrictive effect on pulmonary
function (Table II).
Because today more and more children treated
for esophageal atresia are now entering their adult
life, it is to be expected that many of them will be
found with a number of potentially severe and
complex functional esophageal and/or pulmonary
problems necessitating intense long-term follow-up
on a regular basis to remedy their problem.
Zenker’s diverticulum
Pharyngoesophageal diverticulum originally was
believed to be a pulsion diverticulum enlarging over
time and causing dysphagia by compression of the
esophagus.10
Belsey,11 at the occasion of his honored guest
lecture before The American Association for Tho-
racic Surgery in 1966, emphasized a dysfunction of
the cricopharyngeal muscle as the underlying cause
and presented a series of 45 patients, the majority of
them treated with myotomy and diverticulopexy
resulting in a complete symptomatic relief in 43
patients.
Belsey’s hypothesis later became endorsed
through the developments of manometry. Ellis and
associates12 identified premature relaxation and
contraction as the possible cause of the cricopharyn-
geal dysfunction, while Duranceau13 and Migliore,
Payne, and Jeyasingham14 recorded a more general
dysfunction of the upper esophageal sphincter.
More recently, Cook and coworkers15 proved a
noncompliance of the upper sphincter with an in-
Fig. 2. Contractility pattern of the musculus cricopharyn-
geus in control specimens (A) and Zenker’s diverticulum (B).
Table II. Esophageal atresia: Pulmonary status after
corrected esophageal atresia
TLC VC FEV1 FEV1/VC
Gestational age
, 37 wk, n 5 10 72 69 70 87
$ 37 wk, n 5 37 86 82 82 87
‡ † †
Birth weight
, 10th percentile (n 5 10) 75 69 71 84
. 10th percentile (n 5 37) 82 77 80 86
* * *
Use of contrast
1 (n 5 32) 76 74 78 88
2 (n 5 13) 84 79 79 82
* †
Type of operation
Colon (n 5 7) 68 65 67 88
Anastomosis (n 5 34) 83 80 80 86
* * †
Figures are given as the percent of normal values. TLC, Total lung
capacity; VC, vital capacity; FEV1, forced expiratory volume in 1 second.
*p , 0.05.
†p , 0.005.
‡p , 0.0005.
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creased intrabolus pressure, reflected by the appear-
ance of a large shoulder on the manometric tracing,
to be the underlying pathogenic mechanism.
Systematically taking large biopsy specimens of
the cricopharyngeal muscle and proximal esopha-
geal muscle wall at the time of operation allowed
our group to perform a number of different stud-
ies.16 In a first setting, contractility studies were
performed showing a significant decrease in time-
to-speak twitch, half-relaxation time, and velocity of
force increment (Table III) in specimens taken from
patients with Zenker’s diverticulum as compared
with specimens obtained from control subjects (Fig.
2).
In a subsequent series of biopsy specimens, enzy-
mohistochemistry and enzymoimmunology were
studied for analysis of a series of parameters rou-
tinely used in evaluating neuromuscular disorders.
Almost all parameters were judged normal in the
control specimens, whereas clear abnormalities
were found in the vast majority of biopsy specimens
taken from patients with Zenker’s diverticulum (Ta-
ble IV).
Muscle biopsy tissue from Zenker patients
showed a chaotic pattern of the muscle fibers, with
hypertrophy and atrophy, necrosis, inflammation,
and fibrosis between the fibers (Figs. 3 and 4).
Acetylcholinesterase and neurofilament staining
showed a pathologic absence of coloration in over
50% of the muscle fibers, indicating a more neuro-
genic induced disorder (Fig. 5).
In a final and third setting of biopsies, adenosine
triphosphate metabolism, that is, energy charge, was
measured (Table V). This energy charge appeared
to be decreased and below the normal expected
values in Zenker’s diverticulum as compared with
control specimens, pointing perhaps more toward a
primary myogenic disorder. However, all three of
these studies seem to endorse the concept of the
noncompliant cricopharyngeal and upper cervical
esophageal muscle as the underlying mechanism
underscoring the importance of the extramucosal
myotomy of the cricopharyngeal muscle and proxi-
mal 3 to 4 cm of the cervical esophageal muscle wall,
as was described 30 years ago by Belsey.
From the clinical aspect, patients with Zenker’s
diverticulum have a wide variety of symptoms. Dys-
phagia and regurgitation are the most prominent
ones and resulted in cachexia and aspiration pneu-
monitis in 19% and 32%, respectively, in our expe-
rience with 225 patients.
Impressive in this series is the high incidence of
associated disease of the upper gastrointestinal
tract, especially GE reflux. In a group of 67 patients
who underwent 24-hour pH study, 37 (55%) had a
clear pathologic tracing and 21% had, on endos-
copy, at least esophagitis grade II. The incidence of
documented reflux necessitating a specific antireflux
therapy was 44%.
Historically, treatment of patients with Zenker’s
diverticulum in my institution consisted in a simple
diverticulectomy, but from 1975 onward patients
were systematically treated by myotomy with diver-
ticulopexy (Fig. 6). More recently, with the develop-
ment of videoscopic surgery, a subset of patients
were treated by an endoscopic esophagodiverticu-
lostomy by means of the endoscopic stapler tech-
nique (Table VI).
Among the 36 patients treated with a simple
diverticulectomy between 1953 and 1975, seven sur-
viving patients were traced back. Five were free of
symptoms, but in all five barium swallow showed
either a recurrence or a spastic ring-like indentation
at the level of the cricopharyngeus muscle. Two
patients had symptoms: One had stenosis related to
the operation; the second patient’s symptoms devel-
oped 16 years after diverticulectomy and necessi-
tated reintervention, that is, myotomy and diverticu-
lopexy, to solve the problem.
In the 174 patients who underwent myotomy and
diverticulopexy and four who had only myotomy for
Table III. Contractility studies in five patients with
Zenker’s diverticulum and five controls
TPT
(msec)
1⁄2 RT
(msec)
Amp
(gm)
dP/dT
(gm/msec)
Control 84 70 8.3 0.2
72 70 1.4 0.05
123 165 3 0.06
61.5 123 6 0.08
172 193 4.1 0.5
Total 102.5 124 0.32
(645.2) (655.4) (60.01)
ZD 324 188 0.9 0.006
126 120 1.2 0.07
490 312 0.7 0.01
126 178 0.8 0.05
72 193 0.5 0.01
Total 225 189 0.03
(6156) (666) (60.001)
p , 0.05 p , 0.05 p , 0.05
ZD, Zenker’s diverticulum; TPT, time to peak twitch; 1⁄2RT, half relaxation
time; AMP, amplitude; dP/dT, velocity of force increment.
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a very small but symptomatic Zenker diverticulum,
96.5% had an excellent or very good result. Only
3.5% had a bad result, one patient requiring a
reintervention. In this patient the muscle biopsy was
strongly suggestive for a primary myogenic disease.
Twenty-eight patients have now been followed up
for more than 10 years and up to 19 years, and 27 of
them are completely free of symptoms. More re-
cently, videoscopic esophagodiverticulostomy was
performed in 11 patients by applying a specially
adapted endoscopic stapler on the cricopharyngeal
bar and stapling the diverticular sac to the cervical
esophagus. This endoscopic stapling results in a
V-shaped retraction of cricopharyngeal bar and a
myotomy over approximately 3 cm.17
The results, however, have been less satisfactory,
inasmuch as reoperation for recurrent dysphagia
became necessary in two patients. The recurrent
dysphagia apparently was the result of the formation
of a ridge caused by fibrotic retraction toward the
esophageal lumen at the staple line.
Motor disorders of the esophageal body
The most common motility disorder of the esoph-
ageal body is achalasia. Until the turn of the century,
treatment consisted in some form of dilatation often
performed in group sessions in an outpatient clinic
setting. The introduction of the principle of myot-
omy according to Heller19 offered a more definitive
perspective, and the results of this operation as
published in the literature are excellent or good in
up to 90% of the patients. The most important, still
ongoing debate is whether to add an antireflux
procedure to prevent complications of GE reflux by
prolonged exposure to acid in an amotile esopha-
geal body.
Analysis of 12 larger studies from the literature
shows a 4% incidence of reflux if the myotomy is
combined with an antireflux procedure and a 12%
incidence of reflux if no antireflux procedure is
added. These results are confirmed by my own
rather limited experience in which a long myotomy
is combined with a Belsey Mark IV antireflux pro-
cedure.20
The results of surgery have been challenged over
the past three decades by the development of pneu-
matic balloon dilatation. In my own institution, Van
Trappen and Hellemans21 performed pioneering
work with this method, obtaining good results in
approximately 80% in a series of over 700 patients
and with minimal mortality and morbidity.
Pneumatic dilatation therefore remains the first
therapeutic option in dealing with this condition.
There is, however, no doubt that today minimally
invasive surgery, in its turn, is challenging pneumatic
dilatations. Sinanan and Pellegrini,22 using video-
assisted thoracoscopic surgery, obtained good re-
lief of dysphagia in 92%. They did not add an
antireflux procedure, however, and noticed patho-
logic 24-hour pH tracings in 60% of the patients.
As a result, they switched to a laparoscopic Heller
procedure, combining it with a Dor fundoplica-
tion, and had no further pathologic pH studies.
Similar excellent results were reported by Ancona
and coworkers.23 The results from both surgery
and pneumatic dilatation seem to be superior and
much longer lasting than the results obtained by
the recent introduction of botulism toxin injection
via endoluminal endoscopy.
Diverticula of the esophageal body are uncom-
mon. They mostly appear as epiphrenic diverticula,
and a variety of underlying motor disorders is diag-
nosed in the vast majority of the cases. As a result,
the principles of treatment are the same as in
Zenker’s diverticulum, that is, diverticulectomy or
diverticulopexy associated with a myotomy at the
opposite side of the esophageal wall. Long-term
results from my own experience with 16 diverticula
Table IV. Enzymohistochemical and enzymoimmunologic findings in 15 control specimens and 62 specimens
of Zenker’s diverticulum
Dominant
fiber type Hypertrophy Atrophy Necrosis
Size
variat. Fibrosis
Central
nucleus Inflammation
Nemaline
rods
Ragged
red
fibers Acetylcholinesterase
Neuro
filam.
Control
I:9 1/15 1/15 0/15 2/15 2/15 1/15 0/15 0/15 2/15 0/9 0/9
II:3
Zenker
I:40 32/41 37/41 33/41 40/41 31/41 30/41 21/41 4/41 23/41 33/44 33/44
The denominator gives the number of patients in whom a given parameter was examined.
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of the esophageal body showed an excellent to very
good outcome in 91% of the cases. Today, as for
achalasia, these diverticula can be treated through a
video-assisted thoracoscopic approach, reducing the
access-related morbidity and therefore resulting in a
shorter hospital stay and earlier socioeconomic re-
integration.24
Gastroesophageal reflux disease (GERD)
The first attempts to treat GE reflux as a func-
tional disorder, rather than as an anatomic defect,
were made by Allison25 in the early fifties. Nissen26
developed his technique from a rather incidental
observation of a continent valve after partial esoph-
agectomy, and Belsey developed his Mark IV oper-
Fig. 3. Hematoxylin-and-eosin coloration in control specimen (A) and Zenker’s diverticulum specimen
(B). Irregular shaped patterns, inflammation, increased fibrotic tissue, size variation, and necrosis in
Zenker’s diverticulum are in contrast to the regular shaped organization of the muscle fibers without
necrosis or inflammation in the control specimen.
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ation as a result of different trials designed to
control reflux.
He put the Mark IV operation to the test of time
in his follow-up clinic, meticulously recording the
results before bringing them to public attention
through his publications with Hiebert27 and Skin-
ner.28 The Belsey school later played a major role in
the development and understanding of reflux dis-
ease and its surgical management.
The Mark IV operation had been my standard
technique in the surgical treatment of GE reflux
disease (GERD) until the advent of laparoscopic
surgery. The objective and subjective results of
medium long-term follow-up of a group of 147
Fig. 4. Adenosine triphosphate, pH 4.3. Control (A) and diverticulum specimen (B). The control specimen
shows a predominance of type II (pale colored) fibers, whereas in Zenker’s diverticulum, type I (dark
stained) fibers dominate.
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patients followed up for a mean of 4.5 years showed
an objective and subjective reflux control of 87%
when two or more pathologic examinations were
used as an indicator of objective reflux (Table VII).
The final score, including undesirable side effects,
showed excellent or good results in 77.7% of the
patients, 11% having a bad result.29
The more recent introduction of potent acid
secretion inhibitors, as well as the introduction of
laparoscopic techniques, have been reviving hot
debates about medical versus surgical treatment.
There is no doubt that proton pump inhibitors can
cure a great number of patients with esophagitis.
However, maintaining these results on a long-term
scale seems to be more problematic, recurrent
esophagitis occurring in up to 50% after 5 years of
follow up or more, unless high maintenance doses
are used.30
The advantages claimed by laparoscopic surgery
are shorter hospital stay, earlier social and profes-
sional reintegration, less consumption of pain med-
ication, and cost benefit. Dallemagne,31 Weerts,32
and their colleagues pioneered the laparoscopic
antireflux technique, showing excellent subjective
short-term outcome in more than 90% of the pa-
tients. Their experience resulted in a rapid and
widespread use of the laparoscopic Nissen as the
standard procedure in antireflux surgery. Thus it is
no surprise to notice from the literature a great
variation in reported complications and recurrences
Fig. 5. Acetylcholinesterase coloration. Diverticulum specimen. Only 50% of the fibers are surrounded by
the dark-stained acetylcholinesterase coloration.
Table V. Biochemical studies
No.
ATP
(mmol/gm
dry weight) No.
NAD
(mmol/gm
dry weight) No.
CK
(units/mg
dry weight)
Cricopharyngeus muscle
Zenker 14 5.8 (62.9) 9 0.54 3 1.9 (61)
(p 5 0.033) (p 5 0.011)
Control 6 10.4 (62.2) 6 0.903 3 2 (61.6)
Sternocleidomastoid muscle
Zenker 10 12.1 (64.8)
Control 6 17 (61.7)
ATP, Adenosine triphosphate; NAD, nicotinamide adenine dinucleotide; CK, creatine kinase. Numbers in parentheses are standard deviations.
The Journal of Thoracic and
Cardiovascular Surgery
July 1998
8 Lerut
of up to 20% in some series, all this still at short-
term follow-up.33
Peters and associates34 prospectively compared
open and laparoscopic approaches using a short
floppy Nissen technique. From this study it can be
concluded that in experienced centers the results of
both approaches are the same in the short term,
therefore justifying the use of minimally invasive
surgery provided the indications are correct.
In my opinion, the current indications for surgery
are persistent or recurrent esophagitis and/or symp-
toms despite optimal medical treatment, persistent
regurgitation, noncompliance with the medical man-
agement of the patient, drug-related side effects,
and biliary reflux.
From my own experience with 107 laparoscopic
Nissen operations, a complete subjective and objec-
tive reevaluation was performed in 39 consecutive
patients operated on for at least 1 year. Objective
evaluation consisted in barium swallow endoscopy,
manometry, and 24-hour pH study (Table VIII).
Thirty-seven patients were symptom-free (94.9%).
Five patients (12.8%) had a pathologic 24-hour pH
study. Two patients had an intrathoracic migration of
the fundoplication (4.8%) but had no subjective nor
objective reflux, and one patient showed grade II
esophagitis on endoscopy.
Overall complete subjective and objective reflux
control was seen in 84.7% of this group. Including
anatomic appearance, 32 patients (82%) had a
totally successful correction. In the same time pe-
riod, however, another 113 patients were treated by
open surgery mostly because of redo surgery or
previous major surgery in the upper part of the
abdomen. In this group of patients a variety of as
many as ten different techniques had to be used to
remedy the reflux problem, including resection and
coloplasty in three patients. This experience clearly
illustrates that one single laparoscopic Nissen-type
of operation does not suit all patients, and attempt-
ing to treat all patients by the same technique is
therefore the wrong attitude. GERD is a complex
disease necessitating an in-depth understanding of
the pathogenesis. A whole battery of sometimes
Fig. 6. Zenker’s diverticulum. Before (A) and after (B) extramucosal myotomy and diverticulopexy. Arrow,
Contrast line at the base of the up-ended diverticulum.
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sophisticated investigations may be necessary before
a patient’s particular problem can be correctly ap-
preciated. Inasmuch as diagnosis precedes treat-
ment, no surgery, even so-called minimally invasive
procedures, should be undertaken before the under-
lying cause of the patient’s condition has been
clarified. The further decision-making and eventu-
ally surgical treatment has to follow an algorithm, a
tailored approach. Within this algorithm, laparo-
scopic surgery is indicated in patients with a normal
esophageal body length, as judged by the reducibil-
ity of the GE junction on barium swallow and with a
normal esophageal body motility.35 In the case of
clear motility disorders, a Belsey Mark IV operation
is to be preferred, whereas in the case of shortening,
a lengthening gastroplasty—Collis-Belsey or Collis-
Nissen—is the technique of choice.36
Barrett metaplasia is now recognized as a more
complex form, an end stage of GERD with more
profound motor disorders of the esophageal body
and a more profound mechanically deficient sphinc-
ter mechanism with prolonged exposure to acid and
bile as well.37, 38
This raises the question whether the results of
surgery are comparable with those obtained in the
non-Barrett reflux population. In this respect, I39
analyzed a group of 25 patients with symptomatic
Barrett reflux treated by a Belsey Mark IV opera-
tion and with a follow-up of at least 10 years and up
to 17 years. From this study an increase of symptoms
was seen over the years, from 12% at evaluation
between 1 to 5 years up to 26% at evaluation after
10 to 17 years. The same trend was noticed in
patients who agreed to undergo objective investiga-
tion, with an increase in pathologic 24-hour pH
study from 15.8% up to 50% (six of 12 studies),
although in two of the six studies the pathologic
tracings were only marginally pathologic (Table IX).
The final outcome combining subjective and ob-
jective evaluation showed a satisfactory control of
reflux in 65.3% of these patients. There are very few
studies dealing specifically with long-term follow-up
results after antireflux surgery in patients with Bar-
rett metaplasia.
Sagar and coworkers40 studied the effect of Nissen
fundoplication in 56 patients with proven Barrett
Table VI. Results of surgical treatment of Zenker’s
diverticulum
No. of
patients
Diverticulectomy (1953-1974) 36
Patients followed up 7
Asymptomatic 5
Barium swallow recurrence of
spastic ring-like indentation at
level of cricopharyngeal muscle
Symptomatic 2
Substenosis 1
Recurrence 16 yr postop. 1
Diverticulectomy 1 myotomy
(1975-1996)
174
Mean follow-up 72 mo
Excellent or very good: 96.6%
Bad: 3.4%
Swallowing and/or respiratory
symptoms
6
Reintervention (primary
muscle disease?)
1
Follow-up 10-19 yr 28
Totally asymptomatic 28
Videoscopic diverticuloesophagostomy 11
Reoperation 2
Excellent 4
Good 5
Fair 2
Table VII. Belsey Mark IV: Results of follow-up of
patients (N 5 147) operated on with at least 1 year’s
follow-up*
No.
Objective findings at 1 year
Endoscopy 121
Hiatus hernia 1 (0.8%)
Esophagitis 16 (13.2%)
Radiography 113
Hernia or patulous cardia 4 (3.6%)
Reflux 16 (14.2%)
24-hour pH study 81
Pathologic 11 (13.5%)
Subjective and objective recurrence 19/147 (13%)
*Mean follow-up was 4.4 years (range 1 to 13 years).
Table VIII. Laparoscopic Nissen fundoplication:
Results of follow-up of 39 patients operated on with
at least 1 year’s follow-up*
No.
Objective findings at 1 year
Endoscopy 39
Esophagitis grade I 1 (5.1%)
Esophagitis grade II 1 (5.1%)
Radiography 39
Hernia 2 (5.1%)
24-hour pH study 39
Pathologic 5 (12.8%)
Subjective and objective recurrence 6 (15.3%)
*Mean follow-up was 25 months (range 1 to 3 years).
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metaplasia and documented postoperative patho-
logic acid exposure in 30 patients (53.5%). Most
other available but scarce studies are dealing with a
mixture of Barrett and non-Barrett populations but
are indicative of what to expect on a long-term basis.
Ackerman and coworkers41 reported a 21.5% inci-
dence of persistent or recurrent reflux disease 10 to
20 years after Nissen fundoplication. The incidence
of heartburn was 27%. Luostarinen42 noticed in his
series a wrap dehiscence of 31% and a 26% inci-
dence of recurrent endoscopic esophagitis after 7 to
10 years of follow-up. DeMeester43 documented an
18% incidence of pathologic 24-hour pH studies in
36 patients who volunteered to have this examina-
tion 1 to 10 years after the Nissen fundoplication.
These patients were a subset of a group of 100
consecutive patients treated with a short floppy
Nissen fundoplication and in whom an overall sub-
jective reflux control of 91% was found. Hiebert and
O’Mara44 reported a 75% incidence of good results
up to 25 years after the Belsey Mark IV repair.
All these studies, including ours, seem to be
comparable, showing in general a stabilization after
20 years’ follow-up with a subjective reflux control
around 75%. However, objective evaluation shows a
higher incidence of recurrence on endoscopy and
24-hour pH study45 whereby obviously a number of
patients are remaining subjectively free of symp-
toms. This of course questions the value of antire-
flux surgery in preventing degeneration in Barrett’s
esophagus, a risk that is now widely accepted and
considered as the main contributing factor in the
sharp rise of adenocarcinoma of the esophagus and
GE junction in the Western world.
From the available data it seems that surgery is
scoring better than medical treatment. McCallum
and colleagues46 noted that only 3.4% of the pa-
tients progressed toward dysplasia after surgery
versus 19.7% of the patients receiving medical treat-
ment; this observation was confirmed by another,
randomized study by Ortiz and associates.47
The ultimate question, of course, is whether ade-
nocarcinoma is occurring after successful antireflux
surgery. The data in this respect are scarce. From
most studies it is not clear whether in case of
degeneration the antireflux procedure was indeed
successful or whether, as for example in the study by
McDonald and coworkers,48 occult invasive carci-
noma or carcinoma-in-situ was already present at
the time of the operation; in all three reported cases
in their series of 108 patients the carcinoma devel-
oped within 30 months. Nevertheless, adenocarci-
noma occurring after successful antireflux surgery
has been reported.*
In my aforementioned group of 25 patients, no
malignant disease occurred. Complete or major
* Ho¨lscher HA. Classification des cancers de l’oesophage. Eigh-
teenth J Chir Dig. Rennes. March 1996. Personal communi-
cation.
Table IX. Belsey Mark IV antireflux operation in patients with Barrett’s metaplasia: Results of subjective and
objective evaluation after 10 to 17 years of follow-up (n 5 25)
Subjective symptoms
Objective
Subjective 1 objectiveEndoscopy 24-hour pH
Evaluation at 1-5 yr 3/25 (12%) 4/20 (20%) 3/19 (15.8%) 5/25 (20%)
Evaluation at 10-17 yr 6/23 (26%) 2/14 (14%) 6/12 (50%) 8/23 (34.7%)
2 patients , 5% reflux
n, Number of patients volunteering to undergo different time intervals.
Table X. Belsey Mark IV antireflux operation in patients with Barrett’s metaplasia: Changes in length of
Barrett mucosa at different endoscopic intervals*
Regression
Progression
(n 5 4)
Complete
(n 5 4)
Major
(n 5 3)
4 -. 2 -. 2 -.0 8 -. 8 -. 5 -. 4 (--. 6) 4 -. 7 -. 7 -. 2 (--.3)
3 -. 2 (--.4) -. 2 -. 0 8 -. 0 -. 2 -. 1 3 -. 5
6 -. 1 -. 0 10 -. 9 -. 2 (-. 2) 3 -. 2 (--. 6) -. 2 (--.6) -.4 (--.6)
3 -.0 -. 0 3 -. 7 (-. 9) -. 5 (--.8) -.6
-. Circumferential metaplasia; --. length of scattered islands of metaplasia.
*Figures indicate length (in centimeters) at each endoscopic evaluation during follow-up.
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regression was documented in seven patients (28%),
but surprisingly progression was noticed in as many
as four patients (16%), only one of them having a
documented recurrence of reflux (Table X). This
puzzling and troublesome phenomenon has also
been described by Sagar and colleagues,40 who
noticed a 16% progression, over half of their pa-
tients having symptoms. Eventually, adenocarci-
noma developed in one patient 9 years after an
unsuccessful antireflux procedure.
This uncertainty about the potential risk of de-
generation and the rather occasional complete re-
gression,49-51 as well as the reported progression,
recently generated intensive research in ablation of
the mucosa using photocoagulation or laser.52
Especially when combined with subsequent anti-
reflux surgery, laser ablation seems to result in a
regeneration by squamous cell epithelium of the
destroyed metaplastic area.53 Although the proce-
dure looks very attractive, the side effects of ablation
caused by thermal effects may result in fibrosis and
stricture, jeopardizing the feasibility of this method
as well as the results of subsequent antireflux oper-
ations.
Follow-up and surveillance will be much more
difficult, and at this point it is not known in how
much laser ablation of Barrett’s mucosa effectively
will prevent malignant degeneration, a process that
is believed to be related to a progressive acquisition
of multiple genetic abnormalities over a time lapse
spanning several years.54 The more recent interest
in ablation of the Barrett mucosa by using ultra-
sound, thus avoiding the thermal side effects, may
open some interesting perspectives.
Another topic of intense research is so-called
short Barrett’s esophagus, often represented by
short tongues of metaplasia and in which up to 18%
of intestinal type metaplasia was found.55 In a study
by Clark and coworkers,56 dysplasia was found in
17% of their cases, suggesting an association be-
tween short Barrett’s esophagus and ultrashort (i.e.,
intestinal metaplasia in the cardia) Barrett’s esoph-
agus and adenocarcinoma of the gastroesophageal
junction; they found up to a 43% incidence of
intestinal metaplasia and a 77% incidence of dyspla-
sia in their resected GE junction tumors. In my own
series of adenocarcinoma of the GE junction, an
incidence of 12% dysplasia was recorded.57
As a result, Spechler and colleagues58 concluded
that the classic definition of a 3 cm metaplastic zone
as the true Barrett esophagus is too restrictive. They
proposed columnar-lined esophagus with intestinal
metaplasia irrespective of its length as a more
accurate definition. How often the short and ultra-
short Barrett esophagus is associated with reflux is
not clear. In our institution a study was performed
by Van Vaerenbergh and colleagues59 to assess the
association of microscopic Barrett’s esophagus and
reflux of acid and bile. The prevalence of micro-
scopic Barrett’s esophagus was evaluated in a group
of 56 consecutive patients who were evaluated for
suspected reflux and without apparent Barrett’s
metaplasia at endoscopy. Multiple biopsy specimens
were taken including the cardia in retroversion. In
all patients, 24-hour ambulatory pH and Bilitec
spectrophotometer (Medtronic Synectics, Stock-
holm, Sweden) monitoring was performed. Fifteen
patients with known “classic” Barrett’s esophagus
served as controls (Table XI).
Intestinal microscopic metaplasia at the GE junc-
tion was present in 12 patients (21%). In patients
without microscopic Barrett’s esophagus, esopha-
geal acid exposure was 5.2% 6 0.9% compared with
6.8% 6 2.9% in those with microscopic Barrett’s
esophagus and 14.1% 6 4.1% in those with “classic”
Barrett’s esophagus. The values for bile exposure
were 3.9% 6 1.9%, 9.4% 6 5.7%, and 22.11% 6
6.7%, respectively. From this study, it was concluded
that microscopic Barrett, like classic Barrett but to a
lesser extent, is associated with both acid and bile
reflux. Whether this is linked with a higher risk for
degeneration remains to be studied, but if this is not
the case our concepts about the interrelation be-
tween reflux, Barrett, and degeneration might well
change in the near future.60, 61
Obviously the whole field of antireflux therapy
remains a fascinating subject, and it is likely that
further refinement in instrumentation used for min-
imal invasive surgery and endoluminal manipula-
tion, as well as the further insights into the patho-
genesis of reflux and the development of more
effective drugs (e.g., against bile reflux) will dramat-
Table XI. Microscopic Barrett’s esophagus:
Relationship to acid and bile reflux in symptomatic
patients
No Barrett
(n 5 44)
Microscopic
Barrett
(n 5 12)
Macroscopic
Barrett
(n 5 15)
Acid exposure
(% of time)
5.2 6 0.9 6.8 6 2.9 14.1 6 4.1*
Bile exposure
(% of time)
3.9 6 1.9 9.4 6 5.7 22.1 6 6.7*
*p , 0.005 compared with No Barrett.
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ically change the scenery of antireflux therapy in the
next MILLENNIUM. The actual minimally invasive an-
tireflux operation seems nothing more than a tran-
sitional phase in this rapidly changing evolution.62
Esophageal carcinoma and carcinoma of the GE
junction
Attempts to treat carcinoma of the esophagus
surgically emerged at the beginning of the century.
Torek63 successfully resected the thoracic esophagus
in 1913. Turner64 in 1931 in the United Kingdom
and Denk65 in 1929 in Germany were the first to
perform transhiatal esophagectomy. Oshawa66 in
Japan in 1933 reported resection of the thoracic
esophagus and immediate esophagogastrostomy,
and a similar operation was independently reported
by Adams and Phemister67 in 1938.
Further progress was obtained through the devel-
opments of thoracic surgery largely based on the
experiences gained during World War II. Most
often the main goal was good palliation; according
to a statement by Belsey, “cure is an accident.” The
reasons for the bad reputation concerning esopha-
geal carcinoma are multiple. Poor general condi-
tion, advanced stage at diagnosis, chaotic lymphatic
spread, and multicentric localization are only some
well-proven factors.
Lymph node status seems to be the most impor-
tant single prognostic factor, with involvement in
30% to 80% of reported series.68 In more than 40%
of the recurrences, lymph nodes are involved69: As a
result, mainly two attitudes toward extent of resec-
tion and lymphadenectomy evolved. There are those
who believe that lymph node involvement equals by
definition systemic disease, thus claiming that it is
useless to make efforts to perform wide peritumoral
resections and lymphadenectomy to improve sur-
vival. The standard technique typical for this ap-
proach is transhiatal stripping and use of gastric
tube for reconstruction, as advocated by Orringer,
Marshall, and Stirling.70 Others, like Skinner,71 be-
lieved that radical en bloc esophagectomy had a
beneficial effect on cure rate, even in cases of lymph
node involvement. Mainly in Japan, much attention
has been paid to meticulous extended lymphadenec-
tomy.68 All these efforts are made to obtain a
so-called R0 situation (i.e., no residual microscopic
tumor), because either microscopic or macroscopic
residual tumor leaves the patient with virtually no
chance for cure.
My experience deals with 1147 cases, and resec-
tion was possible in 80%. For tumors located below
the carina, a left-sided transthoracic approach is
used and the diaphragm is opened at its periphery,
offering wide exposure in the chest and abdomen as
well. Besides a wide peritumoral dissection, much
attention is paid to a meticulous lymphadenectomy
around the celiac axis, superior mesenteric artery
and, for tumors of the GE junction, down to the
renal artery, clearing out all tissues in the left upper
abdominal quadrant. In the chest, the posterior
mediastinum is cleaned out including subcarinal
nodes, aortopulmonary window, and thoracic duct.
In tumors of the upper half, a right-sided approach
is used and attention is paid to a meticulous dissec-
tion of lymph nodes along the left recurrent nerve
and brachiocephalic trunk. Reconstruction is per-
formed by using a gastric tube after resecting the
lesser curvature, again for oncologic reasons.
Overall 5-year survival for tumors of the esopha-
gus is 30%,72 for GE junction tumors 33%, and for
Barrett carcinoma 58%, the last figure being influ-
enced by a higher number of early carcinomas (Fig.
7). The stage-by-stage survival in carcinoma of the
esophagus is 90% and 56% for early stage I and II
and 16% for stage III. Lymph node status appeared
to be a most important prognostic factor, with a 63%
5-year survival for patients with node-negative dis-
ease versus 12% for those with node-positive dis-
ease.
In a retrospective study on a subset of patients in
whom the surgeon had the impression of a curative
intervention, we72 compared radical versus nonradi-
Fig. 7. Overall 5-year survival after primary surgery in
tumors of the esophagus, in Barrett’s carcinoma, and in
tumors of the paraesophageal junction (GEJ).
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cal surgery, revealing a significant benefit in favor of
the radical interventions (Fig. 8). Similar results
have been reported by Altorki, Girardi, and Skin-
ner73 and Hagen, Peters, and DeMeester.74 For the
advanced stage, the survival figure confirms that
only a complete R0 resection offers a chance for
cure, up to 20% in this subset of patients.75
In Barrett carcinoma the overall 5-year survival
was as high as 58%, and this relates to a high
number of early-stage carcinomas, with a 100% and
an 87% 5-year survival for stage I and II, respec-
tively. Again, the lymph node status was the most
important prognostic factor, but even in patients
with node-positive disease a 38% 5-year survival was
obtained. The high survival figures, especially in the
early stages, relate to the value of surveillance in
Barrett’s esophagus.
Indeed, three fourths of patients under surveil-
lance had node-negative disease, that is, the major-
ity of those with stage I and II carcinomas, as
opposed to patients who had carcinoma at their first
medical contact and in whom only one fourth had
negative nodes.76
Today much attention is focused on the behavior
of tumors of the GE junction, which we defined as
tumors with the core of the tumor located at the Z
line and within an area of maximum 5 cm orally or
aborally from the anatomic junction between the
esophageal and gastric wall on the resected speci-
men.77 Overall 10-year survival was 31%, and again
high survival figures of 90% and 70% were obtained
in early stage I and II disease, with even a 28%
survival in stage III and an 11% survival in stage IV,
the latter being a rather unexpected finding.
We therefore analyzed separately patients with
intrathoracic lymph node metastasis, that is, stage
IV because of distant lymph node metastasis in the
actual International Union Against Cancer (UICC)
TNM classification.78 Because we found in this
group of patients a gratifying 13% cure rate, we
believe that positive intrathoracic lymph nodes
should not exclude patients from treatment modal-
ity aiming at cure.58
Moreover, these findings raise the question
whether GE junction tumors ought to be classified
as esophageal carcinoma rather than as gastric
carcinoma, as in the actual TNM classification sys-
tem. This question gains validity because much of
the debate is now focusing on Barrett metaplasia
possibly being the common origin of all adenocarci-
nomas of the esophagus and GE junction, as dis-
cussed earlier.60
Adding lymph node dissection in the neck, “the
third field,” as advocated by the Japanese authors, is
believed to improve staging, disease-free survival,
and cure rate.79 In my experience with 37 patients in
whom three-field lymphadenectomy was performed,
no hospital mortality occurred and morbidity, in-
Fig. 8. Five-year survival comparing radical versus nonradical curative resections in tumors of the
esophagus.
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cluding recurrent nerve paralysis, was perfectly com-
parable with that of two-field lymphadenectomy.
The impact on staging was impressive, as 30% of the
patients appeared to have unforseen positive nodes
in the neck, causing a change in pTNM staging in
16% of the whole group as compared with only
two-field lymphadenectomy. Most impressive was
the high incidence of positive cervical nodes in pa-
tients with distal esophageal carcinoma, again 30%.
As a result, more recently an analysis was made of
the pattern of lymph node involvement in patients
with adenocarcinoma of the GE junction. This pat-
tern was compared with that of patients with ade-
nocarcinoma of the distal esophagus. To obtain
comparable groups, the study was restricted to the
T3 N1 subset of patients (Table XII). As many as
16% positive cervical nodes were found with GE
junction carcinoma, whereas 30% were positive with
adenocarcinoma of the distal esophagus. Also, the
intrathoracic and intraabdominal pattern of lymph
node involvement was very similar in both groups.
As expected, differences in percentages were related
to the location of the tumor, but surprising was the
high figure, 50%, of thoracic duct involvement in
distal esophageal carcinoma and the high percent-
age of involved subcarinal and aortopulmonary win-
dow lymph nodes in tumors of the GE junction.
These findings again seem to indicate that tumors of
the GE junction behave more like esophageal car-
cinomas, rather than like gastric carcinomas.
Besides improving staging, three-field lymphade-
nectomy is believed to have a beneficial effect on
lymph node recurrence as first site of recurrence not
only in the neck but also in the mediastinum and
abdomen. In the initial group of 37 patients treated
with three-field lymphadenectomy, six patients
(16%) had local or regional lymph node metasta-
sis—two in the neck, one in the mediastinum, and in
three patients both in the mediastinum and in the
abdomen.
All patients had stage IV disease because of
lymph node metastasis, with more than five positive
nodes in all. Nevertheless, in three of these patients
lymph node metastasis occurred only 3 years or
more after the operation, which seems to endorse
the statement that three-field lymphadenectomy is
indeed improving disease-free survival.
The final and most important question is whether
three-field lymphadenectomy results in an increased
cure rate. At this time it is too early to answer this
question from our own experience. From 1992 until
1993, 100 consecutive patients with carcinoma of the
esophagus and GE junction underwent resection.
There was no hospital mortality.
Disease-specific overall actuarial 5-year survival is
37%. Comparing the radical approach versus the
nonradical approach shows no difference between
stage I and II, but there seems to be a trend in favor
of three-field dissection for the more advanced
stages, that is, 21% versus 12% survival at 4 years
(Fig. 9).
From the Japanese data an advantage favoring
three-field lymphadenectomy has been reported,
whether comparing N status, T status, or different
stages.80-86 However, almost all reported series are
dealing with retrospective studies underlining the
need for prospective randomized studies.
Because of the relatively poor outcome after
primary surgery, much attention has been focused
on multimodality regimens, especially the combina-
tion of chemoradiotherapy in the neoadjuvant set-
ting. A well-documented overview of the available
literature is given by Fink and coworkers.87 A large
number of prospective studies or randomized trials
have been reported mainly from the United States
and to a lesser extent from Europe. It is impossible
to give a detailed analysis of all these studies, and
the following paragraphs are a compilation of the
results from the most relevant studies. In potentially
resectable tumors, four prospective randomized
studies were analyzed88-91 comparing preoperative
chemotherapy followed by surgery with primary
surgery. Resection rate varies from 81% to 92%
for chemotherapy plus surgery versus 70% to 82%
for primary surgery, R0 resection from 35% to
45% versus 21% to 46%, postoperative mortality
from 0% to 19% versus 0% to 10%, and median
survival from 9 to 15 months versus 9 to 12
months. Median survival for responders varied
between 13 and 43 months. These results indicate
that, compared with surgery alone, neither resec-
Table XII. Pattern of lymph node involvement in
adenocarcinoma T3N1
Distal esophagus
(n 5 11)
GE junction
(n 5 16)
Neck, paratracheal 36.3% 16.6%
Carina, main-stem bronchus 20% 22.2%
Aortopulmonary window 5%
Thoracic duct 50% 8.3%
Splenic artery, hilum 14% 61%
Celiac axis 10% 38%
Hepatic artery, portal vein 0% 0%
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tion rate nor survival are significantly influenced
by these regimens.
In locally advanced disease, however, the potential
benefit becomes more evident with a substantial num-
ber of cases being downstaged and converted into
complete resectability especially when using a combi-
nation of chemotherapy and radiotherapy. In three
reported phase III trials92-94 mean R0 resection rate
was 66.4%. Mean postoperative mortality was 10.5%
and median survival 15.3 months and up to 28.2
months after R0 resection. In 15% to 20% of these
patients complete tumor “sterilization” was found on
pathologic examination of the resected specimen.
There is, however, no evidence that these neoadjuvant
regimens are influencing overall cure rates even from
the more recent data from the literature.
Fig. 9. Actuarial survival comparing radical versus nonradical surgery in advanced (stage IIb to IV) tumors
of the esophagus and GE junction. One hundred transthoracic resections were performed from 1992 to
July 1993.
Fig. 10. Actuarial 3-year survival after chemoradiotherapy plus surgery: Outcome in complete pathologic
response versus partial or no response in patients with clinical T4 disease. A total of 26 patients underwent
exploration.
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In the prospective randomized trials reported by
Law,95 Kelsen,96 and their associates (intergroup study
113), chemotherapy plus surgery was compared with
surgery. In the first trial, median survival was 16.8
months versus 13 months for surgery alone, but in the
chemotherapy plus surgery group responders did sig-
nificantly better than the nonresponders, with 42.2
months’ median survival versus 13.8 months.
In the intergroup 113 study, resectability (65% vs
66%), median survival (16.1 vs 16.8 months), 1-year
survival (62% vs 62%), and 2-year survival (38% vs
40%) were almost identical. Urba and coworkers,97
comparing surgery versus chemoradiation plus
surgery, noticed a median survival of 1.46 years
after surgery versus 1.41 years for chemoradiation
plus surgery. However, at 3 years, survival was
15% versus 32% for the multimodality regimen.
In a European multicentric trial published by
Bosset and colleagues,98 chemoradiation plus sur-
gery was compared with primary surgery in clini-
cal early stage I and II squamous cell carcinoma.
Median survival was 18.6 months in both groups,
although induction therapy did prolong disease-
free survival.
More recently, as a result of the increasing inci-
dence of adenocarcinomas, attention has been fo-
cused on multimodality regimens specifically in pa-
tients with adenocarcinoma of the distal esophagus
and GE junction.
Walsh and colleagues99 reported a significant
benefit in patients receiving chemoradiation before
surgery, with a 3-year survival of 32% versus 6% for
surgery alone. However, the trial was criticized
because of the lack of precision in clinical staging
methods, the great variation in surgical approaches,
and the fact that in the authors’ earlier experience a
5-year survival of 20% was obtained with surgery
alone. It seems from the available experience that
neoadjuvant therapy is rather having a locoregional
effect, the chemotherapy component failing to con-
trol distant systemic metastasis. As far as adjuvant,
that is, postoperative modalities are concerned, little
data are available, but a recent multicentric trial
by the Japanese Clinical Oncology Group100 could
not show any survival benefit when adding a cis-
platin- and vindesine-based regimen, obtaining a
48.1% 5-year survival versus 44.1% 5-year survival
for surgery alone.
At our own institution a chemoradiotherapy neo-
adjuvant therapy protocol before surgery was
started for patients with clinical T4 disease. These
tumors are mostly located in the upper half of the
esophagus. Twenty-six of 33 patients underwent
exploration. Twenty-three patients underwent
esophagectomy. Hospital mortality was 9%. In 19%
an R0 resection was achieved and in six patients a
complete sterilization was seen on pathologic exam-
ination. The overall actuarial survival at 3 years is
32%, being 53% for the R0 resections and as much
as 83% for the six patients with complete steriliza-
tion. These figures are definitely superior to those
obtained in our historical controls.
From all these data it becomes clear that surgery
is still the gold standard. Surgeons therefore must
play a major role in setting the future trends in the
treatment of esophageal carcinoma. Multicentric
trials are, in this respect, recommended.
In the future, randomized trials should focus on
three points: (1) Squamous cell carcinoma and adeno-
carcinoma should be assessed separately. The sharp
rise in incidence of adenocarcinoma noticed in the
Western world over recent years requires urgent eval-
uation of the value of chemotherapy and/or radiother-
apy before surgery. (2) It is important to optimize TN
staging by using clinical endosonography101; minimal
invasive surgery and positron emission tomographic
scan may become important tools in staging the dis-
ease.102, 103 (3) Standardization of surgical techniques,
pathologic examination, therapeutic protocols, and
survival curves is crucial.
It is clear, however, that further research has to
focus on pretherapeutic identification of potential
responders, and this is a field in which molecular
biology technology is most likely to play a major role
in the future.104-106 This research needs to be com-
bined with further efforts to develop less toxic
regimens, and more prospective studies are needed
to assess the role, extent, and timing of these
different therapeutic regimens.
R E F E R E N C E S
1. Brewer LA. History of surgery of the esophagus. Am J Surg
1980;139:730-43.
2. Gibson T. Anatomy of humane bodies epitomized. 5th ed.
London. Printed by T.W. for Awnsham and John Churchill
at the Black Swan in Pater-Noster-Row, and sold by Timo-
thy Childe at the White-Hart, the West end of St. Paul’ s
Church Yard, 1697.
3. Haight C, Towsley HA. Congenital atresia of the esophagus
with tracheoesophageal fistula: extrapleural ligation of fis-
tula and end-to-end anastomosis of esophageal segments.
Surg Gynecol Obstet 1943;76:672-88.
4. Waterston DJ, Bonham-Carter RE, Aberdeen E. Oesoph-
ageal atresia: tracheo-oesophageal fistula. A study of sur-
vival in 218 infants. Lancet 1962;1:819-22.
5. Howard R, Myers NA. Esophageal atresia: a technique for
elongation the upper pouch. Surgery 1956;58:725-7.
The Journal of Thoracic and
Cardiovascular Surgery
Volume 116, Number 1
Lerut 1 7
6. Belsey R. Reconstruction of the esophagus with left colon.
J Thorac Cardiovasc Surg 1965;49:33-55.
7. Lerut T. Long gap atresia: management of esophageal
atresia. Willital H, Nihoul-Fe´kete´ C, Myers NA, editors.
Munich: Urban and Schwarzenberg; 1990. pp. 51-5.
8. Pompeo E, Coosemans W, De Leyn P, Deneffe G, Van
Raemdonck D, Lerut T. Esophageal replacement with
colon in children using either the intrathoracic or retroster-
nal route: an analysis of both surgical and long-term results.
Surg Today Jpn J Surg 1997;27:729-34.
9. Van Gysel D, De Boeck K, Lerut T, Willems T, Carrette M,
De Vlieger H, et al. Pulmonary status during childhood
after corrected congenital esophageal atresia. In: Nabeya K,
Hanaoka T, Nogami H, editors. Recent advances in diseases
of the esophagus. Tokyo. Springer Verlag; 1993. p. 2-7.
10. Zenker FA, Von Ziemssen H. Krankheiten des Oesopha-
gus. In: Von Ziemssen H, editor. Handbuch des Specielen
Pathologie und Therapie. Vol. 7 (suppl). Leipzig: FCW
Vogel; 1877. p. 1-87.
11. Belsey RH. Functional diseases of the esophagus. J Thorac
Cardiovasc Surg 1966;52:164-88.
12. Ellis FH, Schlegel JF, Lynch VP, Payne WS. Cricopharyn-
geal myotomy for pharyngoesophageal diverticulum. Ann
Surg 1969;170:340-9.
13. Duranceau A. Pharyngeal and cricopharyngeal disorders.
In: Pearson FG, Deslauriers J, Ginsberg R, Hiebert CA,
McKneally MF, Urschel HC, editors. Esophageal surgery.
New York: Churchill Livingstone; 1995. p. 389-416.
14. Migliore M, Payne H, Jeyasingham K. Pathophysiologic
basis for operation on Zenker’s diverticulum. Ann Thorac
Surg 1994;57:1616-21.
15. Cook IJ, Blumbergs P, Cash K, Jamieson GG, Shearman DJ.
Zenker’s diverticulum: evidence for a restrictive cricopharyn-
geal myopathy. Hepatogastroenterology 1992;7:556-62.
16. Lerut T, Coosemans W, Cuypers Ph, De Leyn P, Deneffe G,
Migliore M, et al. The pharyngoesophageal segment: cervi-
cal myotomy as therapeutic principle for pharyngoesopha-
geal disorders. Dis Esophagus 1996;9:22-32.
17. Collard JM, Otte JB, Kestens PJ. Endoscopic stapling
techniques of esophagodiverticulostomy on Zenker’s diver-
ticulum. Ann Thorac Surg 1993;56:573-6.
18. Russell JC. Diagnosis and treatment of spasmodic stricture
of the oesophagus. Br Med J 1898:1450-1.
19. Heller E. Extramukose Cardioplastik beim chronischen
Cardiospasmus mit Dilatation des Oesophagus. Mitt Grenz
Med Chir 1914;27:141-9.
20. Lerut T. Is Belsey’ s operation preferable if there is a
disorder of esophageal motility? In: Giuli R, Tytgat GNJ,
Demeester TR, Galmiche JP, editors. OESO The esopha-
geal mucosa: 300 questions—300 answers. Amsterdam:
Elsevier Science; 1994. p. 673-6.
21. Van Trappen G, Hellemans J. Treatment of achalasia and
related motor disorders. Gastroenterology 1980;79:144-54.
22. Sinanan PM, Pellegrini CA. The treatment of achalasia and
gastro-esophageal reflux by minimally invasive techniques.
In: Baue AE, Geha AS, Hammond GL, Laks H, Naunheim
KS, editors. Glenn’s thoracic and cardiovascular surgery.
Stamford: Appleton & Lange; 1995. p. 855-62.
23. Ancona E, Anselmino M, Zannionotto G, Costantini M,
Rossi M, Bonavina L, et al. Esophageal achalasia: laparo-
scopic versus conventional open Heller-Dor operation.
Am J Surg 1995;170:265-70.
24. Lerut T. Thoracoscopic esophageal surgery. In: Baue AE,
Geha AS, Hammond GL, Laks H, Naunheim KS, editors.
Glenn’s thoracic and cardiovascular surgery. Stamford:
Appleton & Lange; 1995. p. 865-77.
25. Allison PR. Reflux esophagitis, sliding hiatal hernia, and the
anatomy of repair. Surg Gynecol Obstet 1952,92:419-31.
26. Nissen R. Eine Einfache Operation zur Beinflussung de
reflux esophagitis. Schweiz Med Wochenschr 1956:86;590-5.
27. Hiebert CA, Belsey R. Incompetency of the gastric cardia
without radiologic evidence of hiatal hernia: the diagnosis
and management of 71 cases. J Thorac Cardiovasc Surg
1961;42:352-62.
28. Skinner DB, Belsey RHR. Surgical management of esoph-
ageal reflux with hiatus hernia: long term results with 1030
cases. J Thorac Cardiovasc Surg 1967;55:33-54.
29. Lerut T, Coosemans W, Christiaens R, Gruwez JA. The
Belsey Mark IV antireflux procedure: indications and long-
term results. Acta Gastroenterol Belg 1990;53:585-90.
30. Klinkenberg-Knol EC, Festen HPM, Jansen BMJ, Lamers
CBHW, Nelis F, Snel P, et al. Long-term treatment with
omeprazole for refractory reflux esophagitis: efficacy and
safety. Ann Intern Med 1994;121:161-7.
31. Dallemagne B, Weerts JM, Jahaes C. Laparoscopic Nissen
fundoplication: preliminary report. Surg Laparosc Endosc
1991;1:13B.
32. Weerts JM, Dallemagne B, Hamoir E, et al. Laparoscopic
Nissen fundoplication: detailed analysis of 132 patients.
Surg Laparosc Endosc 1993;3:359-64.
33. Richardson WS, Trus TL, Hunter JG. Laparoscopic antire-
flux surgery. Surg Clin North Am 1996;76:437-50.
34. Peters JH, Heimbucher J, Kauer WK, Incarbone R, Brem-
ner CG, DeMeester TR. Clinical and physiologic compari-
son of laparoscopic and open Nissen fundoplication. J Am
Coll Surg 1995;180:385-93.
35. Kauer WKH, Peters JH, Ireland AP, DeMeester TR,
Heimbucher J, Bremner CG. A tailored approach to anti-
reflux surgery. J Thorac Cardiovasc Surg 1995;109:1-7.
36. Pearson FG, Langer B, Henderson RD. Gastroplasty and
Belsey hiatus hernia repair. J Thorac Cardiovasc Surg
1971;61:50-61.
37. DeMeester TR, Attwood SEA, Smyrk TC. Surgical therapy
in Barrett’s esophagus. Ann Surg 1990;212:528-42.
38. Iascone C, DeMeester TR, Little AG, Skinner DB. Barrett’s
esophagus: functional assessment, proposed pathogenesis,
and surgical therapy. Arch Surg 1983;118:543-9.
39. Lerut T, Coosemans W, De Leyn P, Deneffe G, Van
Raemdonck D. Subjective and objective evaluation then to
seventeen years after Belsey Mark IV in reflux patients with
Barrett’s metaplasia. World J Surg. In press.
40. Sagar PM, Ackroyd R, Hosie KB, Patterson JE, Stoddard
CJ, Kingsnorth AN. Regression and progression of Barrett’s
esophagus after antireflux surgery. Br J Surg 1995;82:806-
10.
41. Ackerman Ch, Margareth L, Mu¨ller C, Harder F. Symptoms
10-20 years after fundoplication. In: Siewert JR, Ho¨lscher
AH, editors. Diseases of the esophagus. Berlin: Springer
Verlag; 1988. p. 1198-202.
42. Luostarinen M. Nissen fundoplication for reflux esophagitis:
long-term clinical and endoscopic results in 109 of 127
consecutive patients. Ann Surg 1993;217:329-37.
43. DeMeester TR. Nissen fundoplication for gastroesophageal
The Journal of Thoracic and
Cardiovascular Surgery
July 1998
1 8 Lerut
reflux disease: the “DeMeester” modification—technique
and results. Dis Esophagus 1996;9:263-71.
44. Hiebert CA, O’Mara CS. The Belsey operation for hiatal
hernia: a twenty year experience. Am J Surg 1979;137:532-5.
45. Horbach JMLM, Gooszen HG, van Beusekom MJL, Jansen
JJ, Lamers CBGW, Terpstra JL. Long-term effect of the
Belsey-Mark IV anti-reflux operation on symptoms and
esophagitis, in relation to postoperative manometry and
24 h pH profile. Dis Esophagus 1994;7:255-61.
46. McCallum RW, Polepalle S, Davenport K, Frierson H,
Boyd S. Role of antireflux surgery against dysplasia in
Barrett’s esophagus. Gastroenterology 1991;100:1-121.
47. Ortiz A, Martinez de Har LF, Parilla P, Morales G, Molina
J, Bernejo F, et al. Conservative treatment versus antireflux
surgery in Barrett’s esophagus: long term results of a
prospective study. Br J Surg 1996;83:274-8.
48. McDonald ML, Trastek VF, Allen MS, Deschamps C,
Pairolero PC. Barrett’s esophagus: Does an antireflux pro-
cedure reduces the need for endoscopic surveillance? J Tho-
rac Cardiovasc Surg 1996;111:1135-40.
49. Brand DL, Ylvisaker JT, Gelfand M, Pope CE. Regression
of columnar esophageal (Barrett’s) epithelium after antire-
flux surgery. N Engl J Med 1980;302:844-8.
50. Deviere J, Buset M, Dumonceau JM, Rickaert F, Cremer
M. Regression of Barrett’s epithelium with omeprazole.
N Engl J Med 1989;320:1497-8.
51. Skinner DB, Walther BB, Riddell RH, Schmidt H, Iascone
C, DeMeester TR. Barrett’s esophagus: comparison of
benign and malignant cases. Ann Surg 1983;198:554-6.
52. Van Laethem JL, Devie`re J, Peny MO, Cremer M. One year
follow-up after complete eradication of Barrett’s esophagus
using argon plasma coagulation (APC). Acta Gastroenterol
Belg 1998;61:C15.
53. Salo JA, Hietala EM, Nemlander A, Va¨a¨na¨nen G, Fa¨rkkila¨
M, Kivilaasko E. Reversal of Barrett’s esophagus by endo-
scopic laser ablation and antireflux surgery. Gastroenterol-
ogy 1994;106:A171.
54. Ferguson MK, Naunheim KS. Resection for Barrett’s mu-
cosa with high grade dysplasia: implications for prophylactic
photodynamic therapy. J Thorac Cardiovasc Surg 1997;114:
824-9.
55. Hogan WJ. Malignant degeneration of Barrett’s esophagus:
malignant potential of “short-segment” Barrett’s esophagus.
Dis Esophagus 1995;8:93-8.
56. Clark GWB, Smyrk TC, Burdiles P, Hoeft SF, Peters JH,
Kiyabu M, et al. Is Barrett’s metaplasia the source of
adenocarcinomas of the cardia? Arch Surg 1994;129:609-14.
57. Steup WH, De Leyn P, Deneffe G, Van Raemdonck D,
Coosemans W, Lerut T. Tumors of the esophagogastric
junction: long-term survival in relation to the pattern of
lymph node metastasis and a critical analysis of the accuracy
or inaccuracy of pTNM classification. J Thorac Cardiovasc
Surg 1996;111:85-95.
58. Spechler SJ, Zeroogran JM, Antonioli DA, Wang HH,
Goyal RK. Prevalence of metaplasia at the gastroesopha-
geal junction. Lancet 1994;334:1533-6.
59. Van Vaerenbergh W, Tack J, Geboes K, Gevers AM,
Rutgeerts P, Lerut T. Microscopic Barrett’s esophagus:
relationship to acid and bile reflux in man. Acta Gastroen-
terol Belg 1998;61:C15.
60. Mendes de Almeida JC, Chaves P, Pereira D, Altorki NK. Is
Barrett’s esophagus the precursor of most adenocarcinomas
of the esophagus and cardia? A biochemical study. Ann
Surg 1997;226:725-35.
61. Schneier PM, Casson AG, Levin B, Gareawal HS, Hoel-
scher AH, Becker K, et al. Mutations of p53 in Barrett’s
esophagus and Barrett’s cancer: a prospective study of
ninety-eight cases. J Thorac Cardiovasc Surg 1996:111:323-33.
62. Kadirkamanathan SS, Evans DF, Gong F, Yazaki E, Scott
M, Swain P. Antireflux operations at flexible endoscopy
using endoluminal stitching techniques: an experimental
study. Gastrointest Endosc 1996;44:133-43.
63. Torek F. The first successful case of resection of the thoracic
portion of the oesophagus for carcinoma. Surg Gynecol
Obstet 1913;16:614-7.
64. Turner GG. The esophagus. London: Cassell and Company;
1946. p. 81-2.
65. Denk W. Zur Radikaloperation des Oesophaguskarzinoms.
Zentralbl Chir 1913;40:1065-8.
66. Oshawa T. The surgery of the oesophagus. Jpn J Surg
1933;10:604-95.
67. Adams W, Phemister DB. Carcinoma of the lower thoracic
esophagus: report of a successful resection and esophago-
gastrostomy. J Thorac Surg 1938;7:621-32.
68. Akiyama H, Masahiko T, Udagawa H, Kijiyama Y. Radical
lymph node dissection for cancer of the thoracic esophagus.
Ann Surg 1994;220:364-73.
69. Isono K, Onada S, Ishikawa T, Seto H, Nakayama K.
Studies on the causes of deaths from esophageal carcinoma.
Cancer 1982;49:2173-9.
70. Orringer MB, Marshall B, Stirling MC. Transhiatal esoph-
agectomy for benign and malignant disease. J Thorac Car-
diovasc Surg 1993;105:265-77.
71. Skinner DB. En bloc resection for neoplasms of the esoph-
agus and cardia. J Thorac Cardiovasc Surg 1983;85:59-71.
72. Lerut T, De Leyn P, Coosemans W, Van Raemdonck D,
Scheys I, Lesaffre E. Surgical strategies in esophageal
carcinoma with emphasis on radical lymphadenectomy. Ann
Surg 1992;216:583-90.
73. Altorki NK, Girardi L, Skinner DB. En bloc esophagectomy
improves survival for stage III esophageal cancer. J Thorac
Cardiovasc Surg 1997;114:948-56.
74. Hagen JA, Peters JH, DeMeester TR. Superiority of ex-
tended en bloc esophagogastrectomy for carcinoma of the
lower esophagus and cardia. J Thorac Cardiovasc Surg
1993;106:850-9.
75. Lerut TE, De Leyn P, Coosemans W, Van Raemdonck D,
Cuypers Ph, Van Cleynenbreughel B. Advanced esophageal
carcinoma. World J Surg 1994;18:379-87.
76. Lerut T, Coosemans W, Van Raemdonck D, Dillemans D,
De Leyn P, Marnette JM, et al. Surgical treatment of
Barrett’s carcinoma: correlations between morphologic
findings and prognosis. J Thorac Cardiovasc Surg 1994;107:
1059-66.
77. Siewert JR, Stein HJ. Carcinoma of the cardia: carcinoma of
the gastroesophageal junction—classification, pathology
and extent of resection. Dis Esophagus 1996;9:173-82.
78. International Union against Cancer (UICC), Hermanek P,
Henson E, Hutter RVP, Sobin LH. editors. Supplement
1993. Berlin/Heidelberg/New York: Springer; 1993.
79. Kato H, Watanabe H, Tachimori Y, Iizuka T. Evaluation of
neck lymph node dissection for thoracic carcinoma. Ann
Thorac Surg 1991;51:931-5.
80. Isono K, Sato H, Nakayama K. Results of nationwide study
The Journal of Thoracic and
Cardiovascular Surgery
Volume 116, Number 1
Lerut 1 9
on the three-field lymph node dissection of esophageal
cancer. Oncology 1991;48:411-20.
81. Kato H, Watanabe H, Tachimori Y, Iizuka T. Evaluation of
neck lymph node dissection for thoracic esophageal carci-
noma. Ann Thorac Surg 1991;51:931-5.
82. Nishihira T, Mori S, Hirayama K. Extensive lymph node
dissection for thoracic esophageal carcinoma. Dis Esopha-
gus 1992;5:79-89.
83. Kato H, Tachimori Y, Mizobuchi S, Igaki H, Ochiai A.
Cervical mediastinal and abdominal lymph node dissection
(three-field dissection) for superficial carcinoma of the
thoracic esophagus. Cancer 1993;72:2879-82.
84. Akiyama H, Tsurumaru M, Udagawa H, Kajiyama Y.
Systemic lymph node dissection for esophageal cancer—
Effective or not? Dis Esophagus 1994;7:151-6.
85. Baba M, Akiko T, Natsugoe S, et al. Long term results of
subtotal esophagectomy with three field lymphadenectomy
for carcinoma of the thoracic esophagus. Ann Surg 1994;
219:310-6.
86. Peracchia A, Fumagalli U, Segalin A, Bonavina L. Congress
Issue—state of the art: pathogenesis, diagnosis and treat-
ment of cancer of the tubular esophagus. Dis Esophagus
1985;8:167-74.
87. Fink U, Stein HJ, Bochtler H, Roder JD, Wilke HJ, Siwert
JR. Neoadjuvant therapy for squamous cell esophageal
carcinoma. Ann Oncol 1994;5:17-26.
88. Roth JA, Pass HI, Flanagan MM, Graeber GM, Rosenberg
JC, Steinberg S. Randomized clinical trial of preoperative
and postoperative adjuvant chemotherapy with cisplatin,
vindesine, and bleomycin for carcinoma of the esophagus.
J Thorac Cardiovasc Surg 1988;96:242-8.
89. Schlag P. For the Chirurgische Arbeitsgemeinschaft fu¨r
Onkologie der Deutschen Gesellschaft fu¨r Chirurgie Study
Group. Randomized trial of preoperative chemotherapy for
squamous cell cancer of the esophagus. Arch Surg 1992;127:
1146-50.
90. Fok M, Wong J. Prospective randomized study of preoper-
ative chemotherapy in the treatment of resectable esopha-
geal carcinoma. Abstract Book, Fifth World Congress In-
ternational Society for Diseases of the Esophagus. Kyoto:
1992. p. 149 A.
91. Kok T, Tilanus G, Obertop H, Van Lanschot J, Van
Blankenstein M, Dees JK, et al. Neoadjuvant chemotherapy
in operable esophageal squamous cell cancer: an interim
report of a randomized controlled trial. Abstract Book,
Fifth World Congress International Society for Diseases of
the Esophagus. Kyoto: 1992. p. 38 A.
92. Bidoli P, Spinazze S, Valente M, Zucali R, Prada A, Cantu
G, et al. Combined chemoradiotherapy 6 esophagectomy in
squamous cell cancer of the esophagus. Proc Am Soc Clin
Oncol 1990;9:110.
93. Fink U, Stein HJ, Lukas P, Gossmann A, Schiffner R,
Dittler HJ, et al. Combined modality treatment for locally
advanced squamous cell esophageal carcinoma located at or
above the level of the tracheal bifurcation. In: Nabeya K,
editor. Diseases of the esophagus. Tokyo: Springer Verlag;
1994. p. 877-83.
94. Wilke H, Stahl M, Fink U, Walz M, Stuschke M, Preusser P,
et al. High pCR/NED rate with an intensive preoperative
combined modality program in patients with esophageal
cancer. Proc Am Soc Clin Oncol 1993;12:215.
95. Law S, Fok M, Chow S, Chu KM, Wong J. Preoperative
chemotherapy versus surgical therapy alone for squamous
cell carcinoma of the esophagus: a prospective randomized
trial. J Thorac Cardiovasc Surg 1997;114:210-17.
96. Kelsen DP, Ginsberg R, Qian C, Gunderson L, Mortimer J,
Estes N, et al. From RTOG, CALBG, SWOG and ECOG.
Chemotherapy followed by operation versus operation alone
in the treatment of patients with localized esophageal cancer:
a preliminary report of intergroup study 113 (RTOG 89-11).
Proc Am Soc Clin Oncol 1997;16:276a (982).
97. Urba S, Orringer M, Turrisa A, Whyte R, Iannettoni M,
Forastiere. A randomized trial comparing surgery (S) to
preoperative concomitant chemoradiation plus surgery in
patients (-pts) with resectable esophageal cancer (CA):
updated analysis. Proc Am Soc Clin Oncol 1997;16:277a
(983).
98. Bosset JF, Gignoux M, Triboulet JP, Tiret E, Mantion G,
Elias D, et al. Chemoradiotherapy followed by surgery
compared with surgery alone in squamous-cell cancer of the
esophagus. N Engl J Med 1997;337:161-7.
99. Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N,
Hennessy TPJ. A comparison of multimodal therapy and
surgery for esophageal adenocarcinoma. N Engl J Med
1996;335:462-7.
100. Ando N, Iizuka T, Kakegawa T, Isono K, Watanabe H, Ide
H, et al. A randomized trial of surgery with and without
chemotherapy for localized squamous carcinoma of the
thoracic esophagus: the Japan Clinical Oncology Group
study. J Thorac Cardiovasc Surg 1997;114:205-9.
101. Van Dam J. Endosonographic evaluation of the patient with
esophageal carcinoma. Chest Surg Clin North Am 1994;104:
510-3.
102. Dagnini G, Caldironi MW, Marin G, Buzzaccarini O,
Tremolada C, Ruol A. Laparoscopy in abdominal staging of
esophageal carcinoma: report of 369 cases. Gastrointest
Endosc 1996;32:400-2.
103. Sugarbaker DJ, Jaklitsch MT, Liptay MJ. Thoracoscopic
staging and surgical therapy for esophageal cancer. Chest
1995;107:2185-235.
104. de Castro J, Baron MG, Feliu J, Gamallo C, Ordonez A,
Espinosa E, et al. Predictive value of p53, E-cadherin and
erb-B2 in patients with squamous cell esophageal carci-
noma. Proc Am Soc Clin Oncol 1997;16:286a (1018).
105. Nabeya Y, Loganzo T, Maslak P, Lawrence L, De Oliveira
AR, Schwartz GK, et al. The mutational status of p53
protein in gastric and esophageal carcinoma cell lines
predicts sensitivity to chemotherapeutic agents. Int J Cancer
1995;64:37-46.
106. Polkowksi W, Van Lanschot JJB, Ten Kate JW, Baak JPA,
Tytgat GNJ, Obertop H, et al. The value of P53 and Ki67 as
markers for tumour progression in the Barrett’s dysplasia-
carcinoma sequence. Surg Oncol 1995;4:163-71.
The Journal of Thoracic and
Cardiovascular Surgery
July 1998
2 0 Lerut
